Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28

Benzinga Newsdesk www.benzinga.com Negative 54.6%

Neg 54.6% Neu 0% Pos 0%

Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and lowers the price target from $35 to $28.